Asset profile

PL2001 · Palatin Technologies, Inc. (PTN)

Indication
rare neuroendocrine obesity disorders (hypothalamic obesity, Prader-Willi syndrome, Bardet-Biedl syndrome)
CompanyPTNPalatin Technologies, Inc.

Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. Its product candidates are targeted, receptor-specific therapeutics for the tre…

On the calendar

Timeline

Newest first.

Nov 14, 2026
12:00 PM
PTNPalatin Technologies, Inc.

Palatin Presents Preclinical Data on MC4R Agonist PL2001 at ObesityWeek 2026

Conference presentationCompany press release

More from Palatin Technologies, Inc.

Other drugs and candidates from the same company tracked in this sector.

PL2001 · Palatin Technologies, Inc. (PTN) — FDA Timeline & Readiness Checklist | SimianX AI